| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.6 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |